Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2013 Jun 10;13(4):430–434. doi: 10.1016/j.clml.2013.03.015

Table 1.

Patient Characteristics

Characteristics Number %
Age
  Median (years) 36
  Range 19–77

Karyotype
  Normal 6 19%
  t(9;22) 4 13%
  t(v;11q23) 3 10%
  Complex (≥3 aberrations) 3 10%
  p16 3 10%
  Other 4 13%
  NA 8 26%

Lactic Dehydrogenase (IU/L)
  Median 755
  Range 145–10,000

White blood cell count (×109/L)
  Median 3.3
  Range <0.1 – 121.4

Treatment Status*
  Salvage 1 6 19%
  Salvage 2 8 26%
  Salvage 3 6 19%
  Salvage 4 6 19%
  Salvage 5 or more 5 16%

ECOG Performance Status
  0 8 27%
  1 17 57%
  2 5 17%
*

Two patients relapsed following an allogeneic SCT prior to enrollment in the trial

Data available on 30 patients only

Abbreviations: ECOG, Eastern Cooperative Oncology Group; NA, not available;